The history of cancer chemotherapy started with the incidental discovery that nitrogen mustard was cytotoxic to lymphoid malignancies. The initial enthusiasm was soon tempered by the observation that most responses were short-lived due to the development of drug resistance.
KeywordsOncol Doxorubicin Methotrexate Resis Neutropenia
Unable to display preview. Download preview PDF.
- Li MC, Whitmore Jr WF, Golbey R, Grabstald H (1960) Effects of combined drug therapy on metastatic cancer of the testis. JAMA 174: 145–153Google Scholar
- Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, De Vita Jr, VT (1986) Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 9: 1295–1306Google Scholar
- National Institutes of Health (1986) Consensus development panel on adjuvant chemotherapy and endocrine therapy for breast cancer. Introduction and conclusions. NCI Monographs 1: 1–17Google Scholar
- Stoter G, Sylvester R, Sleijfer DT, ten Bokkel Huinink WW, Kaye SB, Jones WG, van Oosterom AT, Vendrik CPJ, Spaander P, de Pauw M (1987a) Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Cancer Multiinstitutional Phase III Study. Cancer Res 47: 2714–2718Google Scholar
- Stoter G, Splinter TAW, Child JA, Fossâ SD, Denis L, van Oosterom AT, de Pauw M, Sylvester R for the European Organization for Research on Treatment of Cancer Genito-urinary Group (1987b) Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol 137: 663–667Google Scholar